Cytokines like IL-12 are essential immune system signaling proteins that stimulate cells to respond to infection by initiating immune responses. CTx co-administers IL-12 mRNA with an antigen to enhance vaccine responses, known as molecular adjuvantation. bit.ly/3rAPd6g

Our new preclinical data on IL-12 adjuvantation, which will be presented at #mRNA2023, demonstrate that MOPCTx induces more potent and durable #immunity through targeted expression, offering advantages over traditional vaccine approaches. bit.ly/3rAPd6g International mRNA Health Conference

Combined Tx President and Co-founder #CEO Dr. Romain Micol will present at the 2023 World Vaccine Congress Europe, taking place October 17-19. Stayed tuned for additional details: bit.ly/2RHtaFw #WVCEU World Vaccine Congress

Later this month, our President and Co-founder #CEO, Dr. Romain Micol will be presenting at the 11th International International mRNA Health Conference taking place October 31 – November 2 in Berlin, Germany and virtually. Stayed tuned for additional details: bit.ly/3LSpTjd

MOPCTx enhances mRNA vaccine biodistribution profile, improves organ protection, maintains vaccine efficacy, and enables the option to use molecular adjuvants to increase duration of protection and boost efficacy. Learn more: prn.to/46KjgY9

What is the difference between conventional #mRNA and the #MOPCTx mRNA platform? Our novel #vaccine platform allows for targeted antigen expression at the injection site, while protecting critical organs. Learn more about our vaccine platform: bit.ly/3KClb8y

MOPCTx enhances mRNA vaccine biodistribution profile, improves organ protection, maintains vaccine efficacy, and enables the option to use molecular adjuvants to increase duration of protection and boost efficacy. Learn more: prn.to/46KjgY9

Our research has shown that MOPCTx enhances and focuses #biodistribution in mouse models and non-human primates, which results in a significant decrease in off-target protein expression. Learn more: bit.ly/3KClb8y

Today, we announced that our President and Co-founder #CEO, Dr. Romain Micol will be presenting at the 11th International mRNA Health Conference, October 31 – November 2 in Berlin, Germany and virtually. See the agenda for the conference here: bit.ly/3LSpTjd

This week, President, CEO and Co-founder, Dr. Romain Micol, presented at the 11th International International mRNA Health Conference in Berlin, Germany. For more information about the conference, visit: mrna-conference.com

Do you want to work with leading scientists on cutting-edge #mRNA technology? We are #hiring Scientists/Senior Scientists in Immunology, Virology, Analytical Chemistry, and Biology. Contact us here: combinedtx.com/contact/

To read about the different views on the subject #mRNA therapy regulations within the scientific community, read in BioSpace: biospace.com/article/medici…

Combined Therapeutics’ President, CEO and Co-founder, Dr. Romain Micol, will be attending the 12th Jefferies London Healthcare Conference, held November 14-16, in London UK. For more information about the conference, visit: bit.ly/3phWCUA #JefferiesHealthcare

Yesterday, our President, CEO and Co-founder, Dr. Romain Micol, presented at the LSX Leaders #InvestivalShowcase. We enjoyed connecting with the greater healthcare community! Visit: bit.ly/47eEttM #RNAvaccines

Listen to the interview and story of the woman who pioneered #mRNA vaccines throughout her entire career here in The New York Times: nytimes.com/2021/06/10/pod… #mRNA #vaccine

On Business of Biotech, Combined Therapeutics President and CEO Dr. Romain Micol speaks with host Matt Pillar about the Company’s unique approach to mRNA vaccines in a post-COVID RNA vaccine era. To listen to the episode, go to: bioprocessonline.com/solution/the-b… #mRNA

In this issue of Life Science Leader, Combined Therapeutics President and CEO Dr. Romain Micol weighed in alongside other RNA executives on where he thinks the field of mRNA cancer vaccines is headed. To read the full article, visit: bit.ly/3NcoDIo #mRNA

Combined Therapeutics will be attending #BiotechShowcase in San Francisco, January 8–10, 2024. Register now to meet one-to-one: biotechshowcase.com We look forward to seeing you there! For more information, visit: informaconnect.com/biotech-showca…

Thomas Vancott, Combined Therapeutics CSO, will be presenting on January 8 at 9:30 a. m. Register now to meet one-to-one: biotechshowcase.com

To learn more about Combined Therapeutics’ vision and the team behind the science, visit: combinedtx.com/about/ #RNA #RNAvaccine #science #vaccines